"Bioprinted Amniotic Fluid-Derived Stem Cells Accelerate Healing of Large Skin Wounds"
Current therapies for skin injuries such a serious burns rely on autologous skin grafts; a therapy which is limiting with regards to the number and size of donor sites, allografts; which suffer from the problem of immune rejection, the more recently developed non-cellular dermal substitutes; which are expensive and not cosmetically advantageous or lastly complex biological skin equivalents; which again suffers from pricing and immune rejection problems. However some recent developments show great promise, such as cell spraying and bioprinting technologies which allow for the deposition of cells and biomaterials into precise three-dimensional geometries in order to create anatomically correct structures. Mesenchymal stem cells (MSCs) are considered an attractive cell for use in such techniques due to their therapeutic potential for repair and regeneration of tissues damaged by injury or disease (Maxson et al. and Wang et al.), as are amniotic fluid-derived stem (AFS) cells due to their high proliferation capacity, multipotency, immunomodulatory activity, and lack of significant immunogenicity (De Coppi et al. and Moorefield et al.). In a recent study in Stem Cells Translational Medicine researchers from the laboratory of Shay Sokera at the Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA have shown that while MSCs and AFS cells both function well in wound closure and re-epithelialisation, AFS cells function better partly through increased secretion of trophic factors (Skardala and Macka et al.).